

Anti-tumor Drug Industry Research Report 2024

<https://marketpublishers.com/r/A178C2F42E6CEN.html>

Date: April 2024

Pages: 128

Price: US\$ 2,950.00 (Single User License)

ID: A178C2F42E6CEN

Abstracts

Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.

According to APO Research, The global Anti-tumor Drug market was valued at US\$ million in 2023 and is anticipated to reach US\$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.

United States is the largest market, followed by Japan, and Europe.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Anti-tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-tumor Drug.

The Anti-tumor Drug market size, estimations, and forecasts are provided in terms of revenue (\$ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by

Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Roche

Novartis

Celgene

Bristol-Myers Squibb

Amgen

Johnson & Johnson

Pfizer

Takeda

Eli Lilly

AstraZeneca

Astellas

Merck & Co

Sanofi

Bayer

Biogen Idec

Eisai

Teva

Otsuka

Anti-tumor Drug segment by Type

Cytotoxic Drugs

Non-cytotoxic Drugs

Anti-tumor Drug Segment by Application

Alkylating Agents

Anti-Metabolism Drugs

Platinum Antineoplastic Agents

Anthracycline Antitumor Drugs

Microtubule Stabilizer

Endocrine Therapy Drugs

Immunotherapy Drugs

Gene Therapy Drugs

Targeted Antineoplastic Drugs

Anti-tumor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem,

market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the

market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Anti-tumor Drug companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

Chapter 13: The main points and conclusions of the report.

Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Anti-tumor Drug by Type
 - 2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
 - 2.2.2 Cytotoxic Drugs
 - 2.2.3 Non-cytotoxic Drugs
- 2.3 Anti-tumor Drug by Application
 - 2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
 - 2.3.2 Alkylating Agents
 - 2.3.3 Anti-Metabolism Drugs
 - 2.3.4 Platinum Antineoplastic Agents
 - 2.3.5 Anthracycline Antitumor Drugs
 - 2.3.6 Microtubule Stabilizer
 - 2.3.7 Endocrine Therapy Drugs
 - 2.3.8 Immunotherapy Drugs
 - 2.3.9 Gene Therapy Drugs
 - 2.3.10 Targeted Antineoplastic Drugs
- 2.4 Assumptions and Limitations

3 ANTI-TUMOR DRUG BREAKDOWN DATA BY TYPE

- 3.1 Global Anti-tumor Drug Historic Market Size by Type (2019-2024)
- 3.2 Global Anti-tumor Drug Forecasted Market Size by Type (2025-2030)

4 ANTI-TUMOR DRUG BREAKDOWN DATA BY APPLICATION

- 4.1 Global Anti-tumor Drug Historic Market Size by Application (2019-2024)
- 4.2 Global Anti-tumor Drug Forecasted Market Size by Application (2019-2024)

5 GLOBAL GROWTH TRENDS

- 5.1 Global Anti-tumor Drug Market Perspective (2019-2030)
- 5.2 Global Anti-tumor Drug Growth Trends by Region
 - 5.2.1 Global Anti-tumor Drug Market Size by Region: 2019 VS 2023 VS 2030
 - 5.2.2 Anti-tumor Drug Historic Market Size by Region (2019-2024)
 - 5.2.3 Anti-tumor Drug Forecasted Market Size by Region (2025-2030)
- 5.3 Anti-tumor Drug Market Dynamics
 - 5.3.1 Anti-tumor Drug Industry Trends
 - 5.3.2 Anti-tumor Drug Market Drivers
 - 5.3.3 Anti-tumor Drug Market Challenges
 - 5.3.4 Anti-tumor Drug Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

- 6.1 Global Top Anti-tumor Drug Players by Revenue
 - 6.1.1 Global Top Anti-tumor Drug Players by Revenue (2019-2024)
 - 6.1.2 Global Anti-tumor Drug Revenue Market Share by Players (2019-2024)
- 6.2 Global Anti-tumor Drug Industry Players Ranking, 2022 VS 2023 VS 2024
- 6.3 Global Key Players of Anti-tumor Drug Head office and Area Served
- 6.4 Global Anti-tumor Drug Players, Product Type & Application
- 6.5 Global Anti-tumor Drug Players, Date of Enter into This Industry
- 6.6 Global Anti-tumor Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

- 7.1 North America Anti-tumor Drug Market Size (2019-2030)
- 7.2 North America Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 7.3 North America Anti-tumor Drug Market Size by Country (2019-2024)
- 7.4 North America Anti-tumor Drug Market Size by Country (2025-2030)
- 7.5 United States
- 7.6 Canada

8 EUROPE

- 8.1 Europe Anti-tumor Drug Market Size (2019-2030)
- 8.2 Europe Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 8.3 Europe Anti-tumor Drug Market Size by Country (2019-2024)
- 8.4 Europe Anti-tumor Drug Market Size by Country (2025-2030)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Russia
- 8.10 Nordic Countries

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Anti-tumor Drug Market Size (2019-2030)
- 9.2 Asia-Pacific Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 9.3 Asia-Pacific Anti-tumor Drug Market Size by Country (2019-2024)
- 9.4 Asia-Pacific Anti-tumor Drug Market Size by Country (2025-2030)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 Southeast Asia
- 9.9 India
- 9.10 Australia

10 LATIN AMERICA

- 10.1 Latin America Anti-tumor Drug Market Size (2019-2030)
- 10.2 Latin America Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 10.3 Latin America Anti-tumor Drug Market Size by Country (2019-2024)
- 10.4 Latin America Anti-tumor Drug Market Size by Country (2025-2030)
- 10.5 Mexico
- 10.6 Brazil

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Anti-tumor Drug Market Size (2019-2030)

11.2 Middle East & Africa Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

11.3 Middle East & Africa Anti-tumor Drug Market Size by Country (2019-2024)

11.4 Middle East & Africa Anti-tumor Drug Market Size by Country (2025-2030)

11.5 Turkey

11.6 Saudi Arabia

11.7 UAE

12 PLAYERS PROFILED

12.1 Roche

12.1.1 Roche Company Information

12.1.2 Roche Business Overview

12.1.3 Roche Revenue in Anti-tumor Drug Business (2019-2024)

12.1.4 Roche Anti-tumor Drug Product Portfolio

12.1.5 Roche Recent Developments

12.2 Novartis

12.2.1 Novartis Company Information

12.2.2 Novartis Business Overview

12.2.3 Novartis Revenue in Anti-tumor Drug Business (2019-2024)

12.2.4 Novartis Anti-tumor Drug Product Portfolio

12.2.5 Novartis Recent Developments

12.3 Celgene

12.3.1 Celgene Company Information

12.3.2 Celgene Business Overview

12.3.3 Celgene Revenue in Anti-tumor Drug Business (2019-2024)

12.3.4 Celgene Anti-tumor Drug Product Portfolio

12.3.5 Celgene Recent Developments

12.4 Bristol-Myers Squibb

12.4.1 Bristol-Myers Squibb Company Information

12.4.2 Bristol-Myers Squibb Business Overview

12.4.3 Bristol-Myers Squibb Revenue in Anti-tumor Drug Business (2019-2024)

12.4.4 Bristol-Myers Squibb Anti-tumor Drug Product Portfolio

12.4.5 Bristol-Myers Squibb Recent Developments

12.5 Amgen

12.5.1 Amgen Company Information

12.5.2 Amgen Business Overview

12.5.3 Amgen Revenue in Anti-tumor Drug Business (2019-2024)

12.5.4 Amgen Anti-tumor Drug Product Portfolio

- 12.5.5 Amgen Recent Developments
- 12.6 Johnson & Johnson
 - 12.6.1 Johnson & Johnson Company Information
 - 12.6.2 Johnson & Johnson Business Overview
 - 12.6.3 Johnson & Johnson Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.6.4 Johnson & Johnson Anti-tumor Drug Product Portfolio
 - 12.6.5 Johnson & Johnson Recent Developments
- 12.7 Pfizer
 - 12.7.1 Pfizer Company Information
 - 12.7.2 Pfizer Business Overview
 - 12.7.3 Pfizer Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.7.4 Pfizer Anti-tumor Drug Product Portfolio
 - 12.7.5 Pfizer Recent Developments
- 12.8 Takeda
 - 12.8.1 Takeda Company Information
 - 12.8.2 Takeda Business Overview
 - 12.8.3 Takeda Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.8.4 Takeda Anti-tumor Drug Product Portfolio
 - 12.8.5 Takeda Recent Developments
- 12.9 Eli Lilly
 - 12.9.1 Eli Lilly Company Information
 - 12.9.2 Eli Lilly Business Overview
 - 12.9.3 Eli Lilly Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.9.4 Eli Lilly Anti-tumor Drug Product Portfolio
 - 12.9.5 Eli Lilly Recent Developments
- 12.10 AstraZeneca
 - 12.10.1 AstraZeneca Company Information
 - 12.10.2 AstraZeneca Business Overview
 - 12.10.3 AstraZeneca Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.10.4 AstraZeneca Anti-tumor Drug Product Portfolio
 - 12.10.5 AstraZeneca Recent Developments
- 12.11 Astellas
 - 12.11.1 Astellas Company Information
 - 12.11.2 Astellas Business Overview
 - 12.11.3 Astellas Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.11.4 Astellas Anti-tumor Drug Product Portfolio
 - 12.11.5 Astellas Recent Developments
- 12.12 Merck & Co
 - 12.12.1 Merck & Co Company Information

- 12.12.2 Merck & Co Business Overview
- 12.12.3 Merck & Co Revenue in Anti-tumor Drug Business (2019-2024)
- 12.12.4 Merck & Co Anti-tumor Drug Product Portfolio
- 12.12.5 Merck & Co Recent Developments
- 12.13 Sanofi
 - 12.13.1 Sanofi Company Information
 - 12.13.2 Sanofi Business Overview
 - 12.13.3 Sanofi Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.13.4 Sanofi Anti-tumor Drug Product Portfolio
 - 12.13.5 Sanofi Recent Developments
- 12.14 Bayer
 - 12.14.1 Bayer Company Information
 - 12.14.2 Bayer Business Overview
 - 12.14.3 Bayer Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.14.4 Bayer Anti-tumor Drug Product Portfolio
 - 12.14.5 Bayer Recent Developments
- 12.15 Biogen Idec
 - 12.15.1 Biogen Idec Company Information
 - 12.15.2 Biogen Idec Business Overview
 - 12.15.3 Biogen Idec Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.15.4 Biogen Idec Anti-tumor Drug Product Portfolio
 - 12.15.5 Biogen Idec Recent Developments
- 12.16 Eisai
 - 12.16.1 Eisai Company Information
 - 12.16.2 Eisai Business Overview
 - 12.16.3 Eisai Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.16.4 Eisai Anti-tumor Drug Product Portfolio
 - 12.16.5 Eisai Recent Developments
- 12.17 Teva
 - 12.17.1 Teva Company Information
 - 12.17.2 Teva Business Overview
 - 12.17.3 Teva Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.17.4 Teva Anti-tumor Drug Product Portfolio
 - 12.17.5 Teva Recent Developments
- 12.18 Otsuka
 - 12.18.1 Otsuka Company Information
 - 12.18.2 Otsuka Business Overview
 - 12.18.3 Otsuka Revenue in Anti-tumor Drug Business (2019-2024)
 - 12.18.4 Otsuka Anti-tumor Drug Product Portfolio

12.18.5 Otsuka Recent Developments

13 REPORT CONCLUSION

14 DISCLAIMER

I would like to order

Product name: Anti-tumor Drug Industry Research Report 2024

Product link: <https://marketpublishers.com/r/A178C2F42E6CEN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A178C2F42E6CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970